Mortality from amyotrophic lateral sclerosis in Finland, 1986-1995

Maasilta, Paula; Jokelainen, M; Löytönen, Markku; Sabel, Clive E.; Gatrell, Anthony C.

doi:10.1034/j.1600-0404.2001.00361.x

Cited by 34 publications

(24 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mortality rates have increased in the US [12], Finland [11], Norway [10], Britain [23] and Italy [24]. Similar to our study, a more pronounced trend in women, with a decreasing sex ratio over time, has been found in the US [12], Britain [23], Norway [10] and Finland [11]. These data provide consistency of findings, not only between countries, but also between different health care systems and study designs.…”

Section: Discussionsupporting

confidence: 92%

“…Reports of mortality rates mirror incidence studies and have shown that mortality from MND has increased over time in different parts of the world [10][11][12]. Although they may underestimate incidence, mortality studies based on administrative databases have the advantage of including large sample sizes during long periods, providing robust power for the examination of change over time.…”

Section: Introductionmentioning

confidence: 98%

See 1 more Smart Citation

Changing mortality for motor neuron disease in France (1968–2007): an age-period-cohort analysis

et al. 2011

View full text Add to dashboard Cite

The incidence and mortality of motor neuron disease (MND) increase with age and appear to have increased with time. The examination of period and cohort effects using age-period-cohort (APC) models can help characterize temporal trends. Our objective was to describe mortality from MND in France (1968-2007), and to examine the role of age, period of death, and birth-cohort on changes in mortality. The number of people who died from MND and population statistics (1968-2007) were extracted from French national records. Annual standardized (age/sex) mortality ratios (SMRs) were computed. Using Poisson regression, APC models examined the relationship between mortality rates and age, period of death, and birth-cohort in subjects aged 40-89 years. Deviance/degrees-of-freedom ratios evaluated model fit; ratios close to one indicated adequate fit. Between 1968 and 2007, 38,863 individuals died from MND (mortality rate = 1.74/100,000); 37,624 were aged 40-89 years. SMRs increased from 54 (95% CI = 49-59) in 1968 to 126 (120-132) in 2007. Male-to-female ratios declined from 1.80 in 1968 to 1.45 in 2007. Changing mortality rates were best explained by cohort effects (deviance/degrees-of-freedom = 1.09). The relative risk of dying from MND increased markedly for persons born between 1880 and 1920, and more slowly after 1920. In conclusion, mortality rates for MND increased between 1968 and 2007, and more rapidly in women than men. This increase was better explained by the birth-cohort of individuals than by period effects. Changing environmental exposures may be a possible explanation and these findings warrant the continued search for environmental risk factors for MND.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 98%

Changing mortality for motor neuron disease in France (1968–2007): an age-period-cohort analysis

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Lastly, in this study, 4 patients originally diagnosed as having ALS had MS recorded as the main cause of death, and 1 patient had both MS and MND as primary causes. Of 29 studies, 12 used both primary and secondary causes of death, 6 used only primary causes [12] and 11 did not include that information [15,59,60] .…”

Section: Mortality Data Should Be Based On Underlying and Contributormentioning

confidence: 99%

Can Mortality Data Be Used to Estimate Amyotrophic Lateral Sclerosis Incidence?

et al. 2010

View full text Add to dashboard Cite

Background: Because studies of the incidence of amyotrophic lateral sclerosis (ALS) have uncertain feasibility and high costs, mortality rates are often used to provide an estimate. We performed a systematic review of the literature concerning mortality related to ALS. We aimed to use well-known criteria of good epidemiological practice to assess the methodological quality of the studies. Methods: A Medline and ScienceDirect literature search was performed to identify studies on ALS mortality published from 1971 to 2009. The literature was examined following 6 criteria. Results: Of the 29 studies examined, almost all presented a clear definition of the population at risk, but 55% of the papers did not report on the accuracy of death certificates, and the use of both ‘underlying’ and ‘contributory’ causes of death was identified in only 41% of cases. When comparing ALS mortality data between calendar dates, the codes from the International Classification of Diseases were consistent overall, except in 3 studies. A majority of articles that compared mortality patterns between geographical regions or ethnic groups discussed the key issues of comparability of health care and equality of access. Overall, among the 29 ALS mortality studies, only 3 complied with all the criteria. In 2 of them, the mortality rates were highly consistent with available incidence data. Conclusion: Only few studies on mortality data followed a high-quality methodology. When studies complied with the criteria, they showed good accuracy with regard to incidence rates. The criteria used in this study could also be used to guide future studies based on mortality data.

show abstract

“…Firstly, several studies have argued for an increase in incidence and mortality rates from MS [13] , ALS [14][15][16][17][18] , and PD [19][20][21] in Western countries during the second half of the last century. Whether the trends in the time series might be due to predisposing factors, or, rather, to immediate factors (such as change of registration practice), is an issue open to further analysis.…”

Section: Introductionmentioning

confidence: 99%

Birth Cohort Effects in Neurological Diseases: Amyotrophic Lateral Sclerosis, Parkinson’s Disease and Multiple Sclerosis

et al. 2012

View full text Add to dashboard Cite

Background: Generational differences in disease rates are the main subject of age-period-cohort (APC) analysis, which is mostly applied in cancer and suicide research. This study applied APC analysis to selected neurological diseases: amyotrophic lateral sclerosis (ALS), Parkinson’s disease (PD) and multiple sclerosis (MS). Methods: The analyses were based on Swiss mortality data. Age-stratified data has been available for MS, PD and ALS since 1901, 1921, and 1942, respectively. APC analysis was performed within the framework of logit models. Main effect models were extended by implementing nested effects, i.e. age effects nested in subperiods, in order to account for the fact that age profiles may change for reasons other than generational influences. Results: In preliminary analyses, APC analysis yielded noteworthy birth cohort effects in all three diseases. After implementing nested effects, the birth cohort effects disappeared in ALS, and smoothed out in PD, where they were greater for the generations born before the 1920s. In MS, the birth cohort effects remained stable, and exhibited a peak in cohorts born in the 1910s and 1920s. Conclusions: APC analysis yielded some evidence for birth cohort effects, i.e. predisposing risk factors that may change in historical terms, in MS and PD, but probably not in ALS.

show abstract

Mortality from amyotrophic lateral sclerosis in Finland, 1986-1995

Abstract: In accordance with other countries ALS mortality in Finland is steadily increasing.

Cited by 34 publications

References 12 publications

Changing mortality for motor neuron disease in France (1968–2007): an age-period-cohort analysis

Changing mortality for motor neuron disease in France (1968–2007): an age-period-cohort analysis

Can Mortality Data Be Used to Estimate Amyotrophic Lateral Sclerosis Incidence?

Birth Cohort Effects in Neurological Diseases: Amyotrophic Lateral Sclerosis, Parkinson’s Disease and Multiple Sclerosis

Contact Info

Product

Resources

About